On September 19, Menarini Silicon Biosystems announced the launch of new cloud-based data analysis solution, MSBiosuite. MSBiosuite automated data analysis platform processes NGS data generated from research in liquid biopsy area and formalin-fixed paraffin embedded (FFPE) tissue analysis.
Menarini Silicon Biosystems partnered with BlueBee to develop this bioinformatics solution. Bluebee is a global bioinformatics addressing data analysis needs in genomics and multiomics space. The company provides comprehensive and optimised data solutions to process raw sequencing data into actionable insights to drive large-scale translational research.
MSBiosuite provides improved NGS data processing, interpretation, analysis and reporting for raw sequencing data generated with Menarini’s Ampli1 and DEPArray NGS kits for single circulating tumor cells (CTCs) and FFPE tissue analysis respectively. It also provides information on somatic variation and copy number profile of a target sequence. Though the launch of this solutions, Menarini aims to address several challenges associated with traditional bioinformatics solutions which includes complexity for data management and regulatory compliance. With MSBiosuite, completes Menarini’s single-cell liquid biopsy and FFPE workflows and will support researchers to derive actionable insights with improved efficiency.
Menarini Silicon Biosystems became pioneer in liquid biopsy field through acquisition of CELLSEARCH Circulating Tumor Cell System from Janssen Diagnostics, LLC. CellSearch is the first clinically validated blood test approved by the U.S. Food and Drug Administration for enumeration and detection of circulating tumor cells (CTCs) for patients with metastatic breast, prostate, and colorectal cancers. CTC analysis aids in the early assessment of patient prognosis, thus proving its effectiveness in the treatment of the patient and also providing valuable information to make a clinical decision. The clinical applications of CTCs include the prediction of cancer prognosis, selection, and the monitoring of therapeutic regimens and drug target applications.
The global liquid biopsy market is projected to reach USD 2,047.9 Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%. Factors such as increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for R&D are driving the growth of the market. With huge investments and growing evidence of the uses/applications of liquid biopsy, companies are increasingly looking to move into the liquid biopsy market.
According to Prachi Saxena, Senior Manager, Healthcare Research at MarketsandMarkets™, advanced sequencing methods such as NGS are also contributing to the growth of liquid biopsy market. Next-generation sequencing (NGS) aids in the detection of low levels of ctDNA in the bloodstream, as it offers sensitivity and specificity. In addition to targeting a single gene or a subset of genes, NGS can also identify genome-wide tumor-derived alterations in ctDNA.
The Next-generation sequencing market is projected to reach USD 16.35 billion by 2024 from USD 4.83 billion in 2017, at a CAGR of 19.2% during the forecast period. Advancements in NGS technologies over the years have reduced the costs of sequencing platforms and systems as well as the sequencing process itself. This is one of the major drivers for the growth of the NGS market. In addition, the regulatory and reimbursement outlook for NGS has improved steadily, thereby serving to boost the adoption of sequencing technologies among a wider base of end users than before. Many institutes prefer NGS systems, which have overridden microarray technology. The applications of NGS in cancer treatment and precision medicine are also generating widespread interest. As prices are expected to decrease further in the coming years, NGS-based tests are expected to be considered under health insurance policies for reimbursement.
However, while the costs involved in NGS have reduced to some extent, they have not reached a level where broad adoption across developing markets can be achieved. This is a key restraint to market growth. In addition, there is a need for technologies to effectively analyze the complex data generated by NGS; this is both a challenge for the market in its current state as well as an area of opportunity for market players
Key Players in NGS Market
1 Illumina, Inc.
2 Thermo Fisher Scientific Inc.
3 Perkinelmer, Inc.
Key Players in Liquid Biopsy Market
1 Qiagen N. V.
2. F. Hoffmann-La Roche AG
3 Illumina, Inc..
Source: MarketsandMarkets™ Analysis.
For more information, please write to us at firstname.lastname@example.org